BIOELECTRONICS CORPORATION Non-Invasive Device Addresses the Treatment of Chronic Inflammation
Chronic inflammation poses a significant challenge to modern medicine. While few effective interventions exist, management of the condition often involves removing inflammatory triggers through dietary or lifestyle changes. Additionally, anti-inflammatory medications are commonly used, but their chronic use is costly and associated with significant side effects.
A promising approach for addressing chronic inflammation emerged with the discovery of the inflammatory reflex. Similar to reflexes in the somatic nervous system, this reflex involves both the afferent (incoming) and efferent (outgoing) arms of the vagus nerve. Although vagus nerve stimulation has been shown to suppress pro-inflammatory cytokine levels in the periphery, traditional stimulation techniques are not suitable for chronic vagus nerve stimulation.
BioElectronics PSWT technology and device designs overcome this limitation, providing a convenient, economical, and highly effective alternative for treating chronic inflammation. Given that over one-third of Americans suffer from chronic, systemic inflammation, this development opens an enormous new market opportunity for BioElectronics. The company plans to continue its efforts to provide clinical support and develop new designs for its product line.
Certain information set forth in this release contains forward-looking information, including future-oriented financial information and financial outlook, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Companys business, projects, and joint ventures; (iv) execution of the Companys vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Companys projects; (vi) completion of the Companys projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Companys current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand managements beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or managements estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
IR@bielcorp.com
Copyright 2024 JCN Newswire . All rights reserved.
© Japan Corporate News, source
